SecBot SecBot
SECBOTREPLAY Home › Report › ONC

ONC · CEO 13G/A: 3.6% stake

BeOne Medicines Ltd. · SC 13G/A filed Nov 13, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 2/10

SC 13G/A filed Nov 13, 2026 at 16:05 ET

CEO John Oyler filed an amended Schedule 13G reporting beneficial ownership of 54,065,077 ordinary shares (3.6% of shares outstanding) as of September 30, 2026. The filing is a routine periodic update with no change in stake direction disclosed in the document, and it follows strong Q3 earnings reported eight days earlier.

  • John Oyler beneficially owns 54,065,077 ordinary shares of BeOne Medicines Ltd.
  • Stake represents 3.6% of 1,483,318,035 ordinary shares outstanding as of September 30, 2026.
  • Ownership includes shares held directly, in trusts, retirement accounts, and options/RSUs exercisable within 60 days.
  • Filing is an amendment to Schedule 13G, indicating no change in passive investor status.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access